CGT Catapult Partners with the University of Hertfordshire for Cell and Gene Therapy Course

United Kingdom-based Cell and Gene Therapy Catapult (CGT Catapult) and the University of Hertfordshire announced on Jan. 20, 2020 the launch of a new course directed at analyzing the skills gap in the manufacture of cell and gene therapies as they progress toward manufacturing at scale.

Designed for staff working in cell and gene therapy manufacturing, the three-day course will explore theoretical and practical training on the aseptic manufacturing of cell and gene therapies in line with European regulatory guidance for good manufacturing practice (GMP), according to a CGT Catapult press release. Participants will receive a University of Hertfordshire accredited certificate after completing the course based on assessments of their knowledge, understanding, and practical skills.

“Through our partnership with The Cell and Gene Therapy Catapult including consultation with leading biotech companies developing new cell and gene therapies, together we have created this bespoke course that provides comprehensive training for practitioners working in Advanced Therapy Medicinal Product manufacturing,” said Dr. Salman Rahman, commercial lead in the School of Life & Medical Sciences, University of Hertfordshire, in the press release. “Students on the course will be taught theoretical knowledge including principles and operational aspects necessary for aseptic manufacturing of cell and gene therapy products in line with European regulatory guidance, complemented by practical learning experiences in state-of-the-art clean room facilities.”

“There is an accelerating demand for skills in the UK cell and gene therapy industry as employment, manufacturing space, and the number of ongoing clinical trials increases year on year,” added Keith Thompson, CEO, Cell and Gene Therapy Catapult, in the press release. “We are delighted to collaborate with the University of Hertfordshire in developing this new initiative, which will support professionals and apprentices working in the manufacturing of advanced therapies. By providing training on GMP quality standards which are vital to the manufacture of cell and gene therapies, we are furthering our mission to fuel the continuing growth of the industry.”

Source: CGT Catapult